The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 2, 1997, Pages 91-97

  Vredenburgh, J J ^a,b   Silva, O ^a   Broadwater, G ^a   Berry, D ^a   DeSombre, K ^a   Tyer, C ^a   Petros, W P ^a   Peters, W P ^a   Bast Jr , R C ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone; Marrow; Micrometastases

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BONE MARROW; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PROGNOSIS; RISK FACTOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RISK FACTORS;

EID: 0031160682     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mansi J, Easton D, Berger U, Gazet JC, Ford HT, Bearnaley D, Coombes RC: Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years follow-up. Eur J Cancer 27:1552, 1991.
2. Cote R, Rosen P, Lesser M, Old L. Osborne M: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749, 1991.
3. Diel I, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol 10:1534, 1992.
4. Gianni AM, Natoli C, Sismondi P, Biglia N, Lesti G, Mulieri M, Iacobelli S: Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. Anticancer Res 10:119, 1990.
5. Kirk S, Cooper G, Hoper M, Watt P, Roy AD, Odling-Smee W: The prognostic significance of marrow micrometastases in women with early breast cancer. Eur J Surg Oncol 16:481, 1990.
6. Peters WP, Berry D, Vredenburgh JJ, Hussein A, Rubin P, Elkordy M, Ross M, Henderson IC, Budman D, Norton L, Weiss R, Hurd D: Five year follow-up of high dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving >10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Cl Oncol 14:317 (#933), 1995.
7. Harbeck N, Untch AI, Pache L, Eiermann W: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69:566, 1994.
8. Ross A, Cooper B, Lazarus H, MacKay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Weinter C, Akard L, Jansen J, Coplan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG, Warner N: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patient using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993.
9. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132, 1993.
10. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C: Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709, 1993.
11. Frankel AE, Ring DB, Tringale F, Hsien-Ma S: Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J Biol Resp Mod 4:273, 1985.
12. Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson D, Ring D, Bast RC Jr: Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 43:55, 1989.
13. Chan CM, Baratta FS, Ozzell L, Ceriani R: Monoclonal antibodies BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Research and Treatment 30:243, 1994.
14. Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC Jr, Ceriani RL, Franklin W: Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res 377:637, 1992.
15. Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Cook M, Layfield L, Peters WP, Bast RC Jr: A comparison of immunohisto-chemistry, two-color immunofluorescence and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. Journal of Hematotherapy, 5:57, 1996.
16. Gianni AM, Siena S, Bregni M, DiNicola M, Dodera A, Zambetti M, Orefice S, Salvardori B, Luini A, Greco M, Zucali R, Valagussa P, Bonnadona G: 5-year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with >10 positive nodes. Proc Am Soc Cl Oncol 14:90 (#61), 1995.